Literature DB >> 19122239

ERdj5 sensitizes neuroblastoma cells to endoplasmic reticulum stress-induced apoptosis.

Christophoros G Thomas1, Giannis Spyrou.   

Abstract

Down-regulation of the unfolded protein response (UPR) can be therapeutically valuable in cancer treatment, and endoplasmic reticulum (ER)-resident chaperone proteins may thus be targets for developing novel chemotherapeutic strategies. ERdj5 is a novel ER chaperone that regulates the ER-associated degradation of misfolded proteins through its associations with EDEM and the ER stress sensor BiP. To investigate whether ERdj5 can regulate ER stress signaling pathways, we exposed neuroblastoma cells overexpressing ERdj5 to ER stress inducers. ERdj5 promoted apoptosis in tunicamycin, thapsigargin, and bortezomib-treated cells. To provide further evidence that ERdj5 induces ER stress-regulated apoptosis, we targeted Bcl-2 to ER of ERdj5-overexpressing cells. Targeting the Bcl-2 to ER prevented the apoptosis induced by ER stress inducers but not by non-ER stress apoptotic stimuli, suggesting induction of ER stress-regulated apoptosis by ERdj5. ERdj5 enhanced apoptosis by abolishing the ER stress-induced phosphorylation of eukaryotic translation initiation factor 2alpha (eIF2alpha) and the subsequent translational repression. ERdj5 was found to inhibit the eIF2alpha phosphorylation under ER stress through inactivating the pancreatic endoplasmic reticulum kinase. The compromised integrated stress response observed in ERdj5-overexpressing ER-stressed cells due to repressed eIF2alpha phosphorylation correlated with impaired neuroblastoma cell resistance under ER stress. These results demonstrate that ERdj5 decreases neuroblastoma cell survival by down-regulating the UPR, raising the possibility that this protein could be a target for anti-tumor approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19122239     DOI: 10.1074/jbc.M806189200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Rotenone induces neurotoxicity through Rac1-dependent activation of NADPH oxidase in SHSY-5Y cells.

Authors:  Rituraj Pal; Tanner O Monroe; Michela Palmieri; Marco Sardiello; George G Rodney
Journal:  FEBS Lett       Date:  2013-12-25       Impact factor: 4.124

2.  ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway.

Authors:  G Rajapaksa; F Nikolos; I Bado; R Clarke; J-Å Gustafsson; C Thomas
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

3.  Measurement of hepatic protein fractional synthetic rate with stable isotope labeling technique in thapsigargin stressed HepG2 cells.

Authors:  Juquan Song; Xiao-jun Zhang; Darren Boehning; Natasha C Brooks; David N Herndon; Marc G Jeschke
Journal:  Int J Biol Sci       Date:  2012-01-20       Impact factor: 6.580

Review 4.  Unfolding the unfolded protein response: unique insights into brain ischemia.

Authors:  Thomas H Sanderson; Molly Gallaway; Rita Kumar
Journal:  Int J Mol Sci       Date:  2015-03-30       Impact factor: 5.923

5.  ERdj5 is the ER reductase that catalyzes the removal of non-native disulfides and correct folding of the LDL receptor.

Authors:  Ojore Benedict Valentine Oka; Marie Anne Pringle; Isabel Myriam Schopp; Ineke Braakman; Neil John Bulleid
Journal:  Mol Cell       Date:  2013-06-13       Impact factor: 17.970

6.  The co-chaperone and reductase ERdj5 facilitates rod opsin biogenesis and quality control.

Authors:  Dimitra Athanasiou; Dalila Bevilacqua; Monica Aguila; Caroline McCulley; Naheed Kanuga; Takao Iwawaki; J Paul Chapple; Michael E Cheetham
Journal:  Hum Mol Genet       Date:  2014-07-23       Impact factor: 6.150

7.  Systematic analysis of genetic variants in Han Chinese patients with sporadic Parkinson's disease.

Authors:  Lamei Yuan; Zhi Song; Xiong Deng; Wen Zheng; Yi Guo; Zhijian Yang; Hao Deng
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

8.  Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Authors:  Niels E Franke; Gertjan L Kaspers; Yehuda G Assaraf; Johan van Meerloo; Denise Niewerth; Floortje L Kessler; Pino J Poddighe; Jeroen Kole; Serge J Smeets; Bauke Ylstra; Chonglei Bi; Wee Joo Chng; Terzah M Horton; Rene X Menezes; Renée J P Musters; Sonja Zweegman; Gerrit Jansen; Jacqueline Cloos
Journal:  Oncotarget       Date:  2016-11-15

Review 9.  Recent Advances in Mouse Models of Sjögren's Syndrome.

Authors:  Yunzhen Gao; Yan Chen; Zhongjian Zhang; Xinhua Yu; Junfeng Zheng
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

Review 10.  Modulation of ERQC and ERAD: A Broad-Spectrum Spanner in the Works of Cancer Cells?

Authors:  Gábor Tax; Andrea Lia; Angelo Santino; Pietro Roversi
Journal:  J Oncol       Date:  2019-10-01       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.